Rheumatology

Researchers have identified several clinical characteristics of psoriasis patients that may increase the risk of developing psoriatic arthritis.  A single-center, retrospective cohort study examined the clinical profiles of psoriasis patients to determine the precursors of psoriatic arthritis (PsA), aiming to bridge the gap between psoriasis management and the identification of psoriatic arthritis risk. The study’s...

Guselkumab, a targeted inhibitor of interleukin-23, has emerged as a promising therapy for psoriatic arthritis, offering hope for improved patient outcomes.  A prospective multicenter study aimed to shed light on the effectiveness of using guselkumab for psoriatic arthritis (PsA) management by analyzing the experiences of PsA patients over 6 months. The study also looked at...

Newly published data from a prospective cohort study indicate that diagnosing psoriatic arthritis within 12 weeks after symptom onset may represent a clinical window of opportunity for achieving minimal disease activity and disease remission.  In rheumatoid arthritis, the benefits of early treatment within 12 weeks following symptom onset are well-documented, leading to better remission rates,...

A preliminary clinical trial suggests that topical rosuvastatin or melatonin are effective at controlling psoriatic skin rashes, with significant benefits reported on days 30 and 60. Psoriasis, a chronic inflammatory skin disorder affecting about 3% of the population, typically manifests in adolescence or later adulthood. The most common form is chronic plaque psoriasis, characterized by...

A new clinical study shows that tildrakizumab effectively improves the quality of life and enhances the work productivity of those living with psoriasis. Psoriasis is a prevalent chronic inflammatory disorder affecting about 3% of US individuals aged 20 and older, making it a significant immune-mediated disease in the US. The economic burden of psoriasis is...

An updated review highlights the role of dysregulated adipokines in cardiovascular comorbidities in psoriasis and finds that biologics exert a cardioprotective role in some cases. Psoriasis is a prevalent chronic, inflammatory, multi-organ, systemic disease affecting millions worldwide. Its most common form, plaque psoriasis, manifests as erythematous plaques with silvery scales, notably on the elbows, knees,...

An analysis of microarray data demonstrated impaired apoptosis signaling pathways in CD14+ monocytes in psoriatic arthritis patients, concluding that their increased levels may play an essential role in the disease pathogenesis. Psoriatic arthritis (PsA) is a complex chronic inflammatory condition affecting approximately 30% of patients with psoriasis, leading to functional impairments and increased mortality risk. ...

A prospective follow-up study found that psoriatic arthritis patients with higher synovial immunohistochemical reactivity of IL-17A, DKK1, and TGF-β1 are more likely to benefit from early initiation of biologics. Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting joints and skin in patients with psoriasis. It exhibits progressive and destructive joint changes, with significant pathological...

Although psoriatic arthritis activity indices might suggest disease severity, this retrospective study demonstrated that disease activity levels and severity are two different concepts and not essentially interchangeable. Psoriatic arthritis (PsA) is a complex, chronic, multidomain inflammatory disease. There have been many studies and indices focusing on identifying and classifying disease activity levels. However, much less...